STOCK TITAN

Revelation Biosciences (REVB) CFO gifts 416K shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

REVELATION BIOSCIENCES, INC. (REVB) reported that its Chief Financial Officer, Chester S. Zygmont III, received a restricted stock award of 208,073 shares of Common Stock under the company’s 2021 Equity Incentive Plan. The award vests with 50% on the two-year anniversary of the grant date and the remaining 50% on the four-year anniversary, subject to continued service and possible acceleration upon performance milestones. On the same date, Zygmont made a bona fide gift of 208,073 shares to The Zygmont Family Trust, which now holds 300,136 shares indirectly, and an affiliated LLC holds an additional 2 shares indirectly.

Positive

  • None.

Negative

  • None.
Insider Zygmont Chester Stanley III
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Common Stock F1 208,073 $0.00 $0.00
Gift Common Stock F1 208,073 $0.00 $0.00
Gift Common Stock F1, F2 208,073 $0.00 $0.00
holding Common Stock F3 -- -- --
Holdings After Transaction: Common Stock — 0 shares (Direct); Common Stock — 300,136 shares (Indirect, by Trust); Common Stock — 2 shares (Indirect, by LLC)
Footnotes (3)
  1. F1. These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.
  2. F2. Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.
  3. F3. Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC.
Restricted stock award 208,073 shares Common Stock granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan on 2026-08-17
Award vesting schedule first tranche 50% Portion of restricted shares vesting on the two-year anniversary of the grant date
Award vesting schedule second tranche 50% Portion of restricted shares vesting on the four-year anniversary of the grant date
Gifted shares 208,073 shares Bona fide gift of Common Stock on 2026-08-17 associated with transfer to family trust
Shares held by family trust after transaction 300,136 shares Indirect holdings of Common Stock by The Zygmont Family Trust after gift transaction
Shares held by LLC 2 shares Indirect holdings of Common Stock by Czeslaw Capital Fund, LLC
Gift transactions count 2 Total number of bona fide gift transactions reported in the filing
Gifted shares total 416,146 shares Aggregate number of shares involved in gift transactions as summarized in transactionSummary
restricted stock award financial
"These shares are subject to a restricted stock award granted under the Revelation"
A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.
2021 Equity Incentive Plan financial
"stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan"
bona fide gift financial
"transaction_code_description": "Bona fide gift""
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
vesting financial
"with 50% of the shares vesting on the two-year anniversary of the grant date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
indirect ownership financial
"direct_or_indirect": "I","nature_of_ownership": "by Trust""

FAQ

What equity award did REVB’s CFO receive according to this Form 4?

The CFO received a restricted stock award of 208,073 shares of Common Stock under Revelation Biosciences’ 2021 Equity Incentive Plan, vesting 50% after two years and 50% after four years, subject to continued service and potential performance-based acceleration.

How do the 208,073 REVB shares granted to the CFO vest over time?

The 208,073 restricted shares vest in two tranches: 50% on the two-year anniversary of the grant date and 50% on the four-year anniversary, contingent on the CFO’s continued employment or service and with potential acceleration if certain performance milestones are achieved.

What gift transactions involving REVB stock did the CFO report?

The CFO reported a bona fide gift of 208,073 shares of Common Stock. These shares were transferred to The Zygmont Family Trust, which is associated with the CFO as a trustee, changing the form of ownership from direct to indirect through the trust.

How many REVB shares are now held by The Zygmont Family Trust?

Following the reported transactions, The Zygmont Family Trust holds 300,136 shares of Revelation Biosciences Common Stock indirectly. Chester S. Zygmont III is a trustee of this trust, as disclosed in the filing’s footnotes.

What additional indirect REVB holdings are associated with the CFO?

Beyond the trust, an entity named Czeslaw Capital Fund, LLC holds 2 shares of Revelation Biosciences Common Stock indirectly. Chester S. Zygmont III is disclosed as the sole manager of Czeslaw Capital Fund, LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zygmont Chester Stanley III

(Last)(First)(Middle)
C/O REVELATION BIOSCIENCES, INC.
4660 LA JOLLA VILLAGE DR., SUITE 100

(Street)
SAN DIEGO CALIFORNIA 92122

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/17/2026A208,073(1)A$0208,073D
Common Stock08/17/2026G208,073(1)D$00D
Common Stock08/17/2026G208,073(1)A$0300,136Iby Trust(2)
Common Stock2Iby LLC(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.
2. Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.
3. Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC.
/s/ J.P. Galda, as attorney-in-fact for Chester S Zygmont III08/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)